X0306 4 2020-12-15 0 0001703057 AbCellera Biologics Inc. ABCL 0001352908 Hayden Michael R C/O ABCELLERA BIOLOGICS INC. 2215 YUKON STREET VANCOUVER A1 V5Y 0A1 BRITISH COLUMBIA, CANADA 1 0 0 0 Common Shares 2020-11-06 4 M 0 270000 0.33 A 985750 I See footnote Common Shares 2020-12-15 4 C 0 117647 A 1103397 I See footnote Common Shares 2020-12-15 4 P 0 73665 20.00 A 118245 I By spouse Stock Option (right to buy) 0.33 2020-11-06 4 M 0 270000 0.00 D 2029-09-11 Common Shares 270000 540000 I See footnote Stock Option (right to buy) 2.76 2020-11-18 4 A 0 100000 0.00 A 2030-11-18 Common Shares 100000 100000 D Convertible Note 2020-12-11 4 A 0 2000000.00 2000000.00 A Common Shares 117647 2000000.00 I See footnote Convertible Note 17.00 2020-12-15 4 C 0 2000000.00 0.00 D Common Shares 117647 0 I See footnote These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein. On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. The exercise price reported above was converted from the Canadian exercise price of CAD $0.43 using an exchange rate of CAD $1.27840 = US $1.00. 50% of the shares subject to such option vest and become exercisable on September 11, 2021 and 50% of the shares subject to such option vest and become exercisable on September 11, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. The exercise price reported above was converted from the Canadian exercise price of CAD $3.52 using an exchange rate of CAD $1.27840 = US $1.00. 100% of the shares subject to such option vest and become exercisable on the date of the 2021 annual general meeting of the Issuer, subject to the Reporting Person's continuous service to the Issuer on such date The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share. This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. /s/ Tryn Stimart, attorney-in-fact 2020-12-17